Business Wire

In New Clinical Study Masimo’s Oxygen Reserve Index Helps Clinicians Detect Impending Desaturation in Pediatric Patients

Del

Masimo (NASDAQ: MASI) announced today that in a new clinical study, Masimo’s Oxygen Reserve Index (ORI™), the first noninvasive and continuous parameter to provide insight into patients’ oxygen reserve when they are receiving supplemental oxygen, helped clinicians in the early identification of impending desaturation in pediatric patients during induction of anesthesia.1

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160204005527/en/

Masimo Root® with ORI™ (Photo: Business Wire)

Masimo Root® with ORI™ (Photo: Business Wire)

Oxygen saturation (SpO2) using pulse oximetry provides noninvasive, continuous visibility to arterial blood oxygenation in hypoxia (lower than normal oxygenation) and normoxia (normal oxygenation). For procedures such as induction of anesthesia and intubation, clinicians will usually build an “oxygen reserve” in the patient by providing supplemental oxygen or “pre-oxygenation,” creating a transitional state of hyperoxia (higher than normal oxygenation). The extent of hyperoxia can be determined by the measured partial pressure of oxygen in the blood (PaO2), which requires invasive arterial blood sampling and laboratory analysis. When patients have low oxygen reserve prior to intubation of the trachea, they are susceptible to sudden hypoxia, depending upon the time taken to perform the intubation.

ORI, Masimo’s 11th rainbow® parameter2, is a relative index of the partial pressure of oxygen in arterial blood (PaO2) within the range of 100 to 200 mmHg that can provide insight into significant changes in oxygen reserve. ORI is intended to supplement, not replace, SpO2 monitoring and PaO2 measurements.

In a prospective study published in Anesthesiology and conducted at Children’s Medical Center in Dallas, Texas, Dr. Peter Szmuk and colleagues evaluated whether ORI could provide a clinically important warning of impending desaturation in pediatric patients with induced apnea after pre-oxygenation. The investigators enrolled 33 patients in this study. Eight of these resumed spontaneous ventilation during the study period, leaving 25 apneic patients to evaluate, with an average age of 7.6 years. Data were recorded continuously by the Masimo Radical-7® Pulse CO-Oximeter®, connected to the patient through an R1 25L rainbow® sensor. ORI was retrospectively calculated and was not visible to investigators.

After pre-oxygenation with supplemental oxygen, anesthesia induction, and endotracheal intubation, the anesthesia circuit was disconnected and SpO2 was allowed to decrease to 90% before ventilation recommenced. During the period of apnea, the ORI progressively decreased from a mean of 0.73±0.2 at the beginning of apnea to 0.37±0.1. The SpO2 remained at 100% during this initial period. After decreases in ORI that would trigger the ORI alarm if monitored in real time, there was a median elapsed time of 31.5 seconds before the SpO2 decreased to 98%. After reinstitution of ventilation, SpO2 values declined further to 88%, before recovering to 98%, 34 seconds later. The researchers concluded that “In this pilot study, we found that during prolonged apnea in healthy anesthetized children, the ORI detected impending desaturation in median of 31.5 seconds (IQR, 19 to 34.3 seconds) before noticeable changes in SpO2 occurred. Knowing even roughly how much time remains before the rapid desaturation phase begins seems likely to guide proper decisions.”

Radical-7® with Root® has a CE Mark with the ORI parameter. ORI is not FDA cleared and is not available for sale in the United States.

@MasimoInnovates | #Masimo

1. Szmuk P, Steiner JW, Olomu, PN, Ploski, RP, Sessler, DI, Ezri, T. Oxygen Reserve Index A Novel Noninvasive Measure of Oxygen Reserve—A Pilot Study. Anesthesiology 2016; 124:00-00. doi:10.1097/ALN.0000000000001009.

2. 11 parameters include: 1) Oxygen saturation (SpO2); 2) Pulse rate; 3) Perfusion index (PI); 4) Pleth Variability Index (PVI®); 5) Respiration Rate from the pleth (RRp®); 6) Total hemoglobin (SpHb®); 7) Oxygen Content (SpOC™); 8) Carboxyhemoglobin (SpCO®); 9) Methemoglobin (SpMet®); 10) Fractional oxygen saturation (SpfO2®); 11) Oxygen Reserve Index (ORI™)

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. The benefits of Masimo SET® have been proven in more than 100 independent and objective studies and it is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive open architecture patient monitoring and connectivity platform designed to speed the pace of innovation and reduce the cost of care. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo’s Oxygen Reserve Index (ORI™). These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including ORI™, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Funds Affiliated with Apollo Global Management and Apeiron Management Establish Partnership to Pursue Corporate Credit Investment Opportunities in Italy22.2.2018 14:00Pressemelding

Funds affiliated with Apollo Global Management, LLC (together with its consolidated subsidiaries, “Apollo”) (NYSE: APO) today announced a strategic partnership with Apeiron Management SpA (“Apeiron”) to focus on investments in Italian corporate credit opportunities. The initiative targets innovative financing solutions for Italian corporate borrowers, and investments in impaired loans, claims, and other credit instruments tied to Italian companies, with the view to capitalizing on the country’s strong manufacturing base, ongoing banking reform, and improved bankruptcy legislation. The partnership will focus primarily on stressed and distressed opportunities, insolvency compositions, and non-performing corporate credit in Italy. Capital will be deployed via debt and equity investments in the EUR 5 million to EUR 50 million range, with the capacity to pursue larger transactions opportunistically. To accomplish these goals, Apollo has established Apollo Delos (“Delos”) as a dedicated inve

Mother Who Lost Infant Son to Medical Error to Join Panel at World Patient Safety, Science & Technology Summit22.2.2018 13:00Pressemelding

New mother Deahna Visscher was feeling hopeful. Although her son Grant had been born with a heart defect, he was doing very well after surgery. Just 11-days old, doctors felt he could soon leave the hospital. But that didn’t happen. A nurse incorrectly inserted a feeding tube piercing the little infant’s trachea and filling his lungs with fluid. “The nurse asked me to go out into the hall and ask for help,” recalls Deahna. “I told them my son was turning blue and I watched as 20 staff members tried to resuscitate him. “ Grant was pronounced dead at 9:10 p.m. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005694/en/ Deahna Visscher will share her personal experience of losing her 11-day old son to a medical error. (Photo: Business Wire) Since that tragic night in 2008, Deahna Visscher has become a fierce patient advocate. The Patient Safety Movement Foundation (PSMF) is happy to announce her participation in a compelling

Westinghouse Electric Company Signs Cooperation Agreement for Lead-Cooled Fast Reactor Development22.2.2018 13:00Pressemelding

Westinghouse Electric Company has signed a Cooperation Agreement for lead-cooled fast reactor (LFR) technology development with the Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) and Ansaldo Nucleare. The agreement demonstrates each party’s commitment to collaborating toward the development of a next-generation nuclear plant based on LFR technology, which is both “walk-away” safe and economically competitive across global energy markets. “This agreement is an exciting step towards the development of a lead-cooled fast reactor for the marketplace,” said Ken Canavan, Westinghouse chief technology officer and vice president, Global Technology Office. “The LFR is game-changing technology for clean energy industries, and Westinghouse is pleased to be working with such experienced partners to bring this innovative concept to fruition.” Beyond baseload electricity generation, the high-temperature operation of the LFR will allow for a broad ran

Mavenir Teams with Dell EMC to Deliver Expanded Cloud-Native NFV Solutions22.2.2018 13:00Pressemelding

Mavenir, a leader in mobile network transformation, today announced its collaboration with Dell EMC OEM Solutions to deliver a broad range of solutions for service providers and enterprises covering 5G Cloud RAN, Packet Core, IoT, VoLTE, VoWiFi and RCS on Mavenir’s cloud-native Open Stack NFV and container CloudRange™ platform. Communications service providers are under intense pressure to simultaneously drive new revenue streams and aggressively reduce costs as OTTs gain market share in voice and messaging services. This expanded collaboration directly addresses these challenges, bringing together Mavenir’s extensive software stack for mobile network providers and Dell EMC solutions for infrastructure, cloud and IOT to create new offerings and best practices that enable the cost effective and rapid evolution of service provider and enterprise networks. Mavenir and Dell EMC OEM will pursue advanced engineering engagements in Cloud RAN, IOT and Enterprise Private LTE Solutions, includin

Equifax Integrates Entersekt’s Digital Security System22.2.2018 12:35Pressemelding

Entersekt, a leader in push-based authentication and mobile app security, today announced a technology partnership with global information solutions company Equifax Inc. (NYSE:EFX). Equifax has licensed Entersekt’s product Transakt to serve as an additional layer of security protecting the Equifax online and mobile services. Transakt empowers consumers to play an active role in safeguarding their digital identities and accounts. Whenever access to a digital identity or account is required, an authentication request is pushed to their phone or tablet in real time. They approve or block access by simply tapping Accept or Reject. It’s a highly intuitive, one-touch user experience engineered for a mobile-first world. Transakt’s ease of use belies its advanced set of security features. Covered by 56 patents in the United States and elsewhere, the digital-certificate–based technology uniquely identifies each registered mobile device; ensures its continued integrity as a factor of authenticat

ImmerVision to Showcase AI-Ready Vision Technology at MWC 201822.2.2018 12:00Pressemelding

ImmerVision, a technology company enabling intelligent vision in all the world’s devices, announced today that it is uniquely prepared to provide AI-ready, data-rich image processing to today’s most incisive device makers and manufacturers. Indeed, ImmerVision is already providing such hyper-intelligent image capture capabilities to some of the world’s top brands. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005513/en/ ImmerVision Enables AI-ready intelligent devices include Acer Holo360, Quanta Pi SOLO, and Tamaggo 360LiveCam (Graphic: Business Wire) Based in Montreal, Canada, ImmerVision develops wide-angle panomorph lenses and data-augmented imaging algorithms, enabling creative manufacturers to see more and smarter while creating professional and consumer devices. “In our quest to enable intelligent vision in every device, ImmerVision has taken a great leap forward,” says Alessandro Gasparini, Executive Vice Presi